Comparing KindlyMD (NAKA) & Its Competitors

KindlyMD (NASDAQ:NAKA) is one of 341 publicly-traded companies in the “Financial Services” industry, but how does it weigh in compared to its competitors? We will compare KindlyMD to similar companies based on the strength of its earnings, profitability, institutional ownership, dividends, risk, analyst recommendations and valuation.

Volatility and Risk

KindlyMD has a beta of 16.03, meaning that its share price is 1,503% more volatile than the S&P 500. Comparatively, KindlyMD’s competitors have a beta of 2.33, meaning that their average share price is 133% more volatile than the S&P 500.

Institutional and Insider Ownership

43.2% of shares of all “Financial Services” companies are held by institutional investors. 24.1% of KindlyMD shares are held by company insiders. Comparatively, 21.9% of shares of all “Financial Services” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares KindlyMD and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
KindlyMD	-1,067.93%	-63.45%	-41.04%
KindlyMD Competitors	-409.42%	-15.09%	-6.08%

Earnings & Valuation

This table compares KindlyMD and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
KindlyMD	$1.82 million	-$52.23 million	-0.17
KindlyMD Competitors	$6.69 billion	$1.09 billion	9.14

KindlyMD’s competitors have higher revenue and earnings than KindlyMD. KindlyMD is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations and price targets for KindlyMD and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KindlyMD	1	0	3	0	2.50
KindlyMD Competitors	1974	6896	11644	443	2.50

KindlyMD presently has a consensus target price of $20.00, indicating a potential upside of 233.89%. As a group, “Financial Services” companies have a potential downside of 7.82%. Given KindlyMD’s higher possible upside, equities research analysts plainly believe KindlyMD is more favorable than its competitors.

Summary

KindlyMD competitors beat KindlyMD on 9 of the 13 factors compared.

KindlyMD Company Profile

Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.